Login to Your Account



NewCo News

Shkreli's Retrophin Eyes Public Markets to Fund Rare Diseases

By Trista Morrison
Staff Writer

Monday, March 12, 2012

Martin Shkreli has never been one to go with the flow. The hedge fund manager at MSMB Capital Management is known for activism: He helped derail the proposed merger between AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc., fought Pfizer Inc.'s decision to replace CEO Jeff Kindler with an insider and has pushed out several health care CEOs he felt weren't doing their jobs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription